Is REGN Stock Undervalued?

A comprehensive valuation analysis of Regeneron Pharmaceuticals Inc (REGN) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated July 13, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

10356122118.1% upside potential

Based on our analysis, Regeneron Pharmaceuticals Inc appears to be potentially undervalued at the current price of $660.70. Our fair value estimate of $68422899495.00 suggests upside potential of approximately 10356122118.1%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing REGN relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

13.91

Low

P/B Ratio

N/A

P/S Ratio

N/A

EV/EBITDA

N/A

Understanding the Metrics

P/E Ratio: At 13.91x earnings, REGN is trading below the typical market average of 15-20x.
P/B Ratio: Book value data not available.
P/S Ratio: Revenue data not available.
EV/EBITDA: EBITDA data not available.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Regeneron Pharmaceuticals Inc stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$660.70

Fair Value Estimate

$68422899495.00

Implied Return+10356122118.1%

Our DCF model suggests REGN may be undervalued by approximately 10356122118.1%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Historical Valuation Trends

Looking at REGN's valuation history helps us understand whether the current multiples are typical or unusual for this company.

Current P/E Ratio

13.91

5-Year Average P/E

13.91

Near historical average

REGN's P/E ratio is near its historical average, indicating the market is valuing the company consistently with past trends.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Regeneron Pharmaceuticals Inc (REGN) appears to be undervalued at $660.70. With a fair value estimate of $68422899495.00, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.